請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16550
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄧哲明(Che-Ming Teng) | |
dc.contributor.author | Mei-Chuan Chen | en |
dc.contributor.author | 陳美全 | zh_TW |
dc.date.accessioned | 2021-06-07T18:20:18Z | - |
dc.date.copyright | 2012-03-02 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-01-09 | |
dc.identifier.citation | Ackerman, P., C. V. Glover and N. Osheroff (1985). Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proc Natl Acad Sci U S A 82(10): 3164-3168.
Alchanati, I., C. Teicher, G. Cohen, V. Shemesh, H. M. Barr, P. Nakache, D. Ben-Avraham, A. Idelevich, I. Angel, N. Livnah, S. Tuvia, Y. Reiss, D. Taglicht and O. Erez (2009). The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target. PLoS One 4(12): e8104. Altieri, D. C. (2008). Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8(1): 61-70. Banath, J. P. and P. L. Olive (2003). Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 63(15): 4347-4350. Bekker-Jensen, S. and N. Mailand (2010). Assembly and function of DNA double-strand break repair foci in mammalian cells. DNA Repair (Amst) 9(12): 1219-1228. Bertrand, P. (2010). Inside HDAC with HDAC inhibitors. Eur J Med Chem 45(6): 2095-2116. Blagosklonny, M. V. and W. S. El-Deiry (1998). Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75(6): 933-940. Bojanowski, K., O. Filhol, C. Cochet, E. M. Chambaz and A. K. Larsen (1993). DNA topoisomerase II and casein kinase II associate in a molecular complex that is catalytically active. J Biol Chem 268(30): 22920-22926. Bots, M. and R. W. Johnstone (2009). Rational combinations using HDAC inhibitors. Clin Cancer Res 15(12): 3970-3977. Catalano, M. G., N. Fortunati, M. Pugliese, R. Poli, O. Bosco, R. Mastrocola, M. Aragno and G. Boccuzzi (2006). Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191(2): 465-472. Chamovitz, D. A. and D. Segal (2001). JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep 2(2): 96-101. Chen, C. S., Y. C. Wang, H. C. Yang, P. H. Huang, S. K. Kulp, C. C. Yang, Y. S. Lu, S. Matsuyama and C. Y. Chen (2007). Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 67(11): 5318-5327. Chen, C. S., S. C. Weng, P. H. Tseng and H. P. Lin (2005). Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280(46): 38879-38887. Chen, T. H., S. L. Pan, J. H. Guh, C. H. Liao, D. Y. Huang, C. C. Chen and C. M. Teng (2008). Moscatilin induces apoptosis in human colorectal cancer cells: a crucial role of c-Jun NH2-terminal protein kinase activation caused by tubulin depolymerization and DNA damage. Clin Cancer Res 14(13): 4250-4258. Chen, W., X. Wang, J. Zhuang, L. Zhang and Y. Lin (2007). Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 28(10): 2114-2121. Cope, G. A. and R. J. Deshaies (2006). Targeted silencing of Jab1/Csn5 in human cells downregulates SCF activity through reduction of F-box protein levels. BMC Biochem 7: 1. d'Adda di Fagagna, F. (2008). Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 8(7): 512-522. Dawlaty, M. M., L. Malureanu, K. B. Jeganathan, E. Kao, C. Sustmann, S. Tahk, K. Shuai, R. Grosschedl and J. M. van Deursen (2008). Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell 133(1): 103-115. Duffy, M. J., N. O'Donovan, D. J. Brennan, W. M. Gallagher and B. M. Ryan (2007). Survivin: a promising tumor biomarker. Cancer Lett 249(1): 49-60. Ekstrom, K., K. Hoffman, T. Linne, B. Eriksson and B. Glimelius (1998). Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study. Oncol Rep 5(4): 931-934. Fan, J. R., A. L. Peng, H. C. Chen, S. C. Lo, T. H. Huang and T. K. Li (2008). Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses. DNA Repair (Amst) 7(3): 452-463. Gatzemeier, U., A. Pluzanska, A. Szczesna, E. Kaukel, J. Roubec, F. De Rosa, J. Milanowski, H. Karnicka-Mlodkowski, M. Pesek, P. Serwatowski, R. Ramlau, T. Janaskova, J. Vansteenkiste, J. Strausz, G. M. Manikhas and J. Von Pawel (2007). Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25(12): 1545-1552. Geiss-Friedlander, R. and F. Melchior (2007). Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8(12): 947-956. Goksel, T., O. N. Hatipoglu, C. Ozturk, M. Gorguner, M. Kiyik, U. Yilmaz, A. Guzelant, S. Tasbakan, E. Tabakoglu, H. Firat, U. Tutar, S. Cikrikicioglu, A. Akkoclu, S. Soyer, E. Cakir, O. Itil and S. Sanal (2005). A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer. Respirology 10(4): 456-463. Gridelli, C., M. A. Bareschino, C. Schettino, A. Rossi, P. Maione and F. Ciardiello (2007). Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 12(7): 840-849. Hande, K. R. (1998). Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34(10): 1514-1521. Harari-Steinberg, O. and D. A. Chamovitz (2004). The COP9 signalosome: mediating between kinase signaling and protein degradation. Curr Protein Pept Sci 5(3): 185-189. Harker, W. G., D. L. Slade, R. L. Parr, P. W. Feldhoff, D. M. Sullivan and M. H. Holguin (1995). Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55(8): 1707-1716. Herbst, R. S., D. Prager, R. Hermann, L. Fehrenbacher, B. E. Johnson, A. Sandler, M. G. Kris, H. T. Tran, P. Klein, X. Li, D. Ramies, D. H. Johnson and V. A. Miller (2005). TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25): 5892-5899. Higgins, B., K. Kolinsky, M. Smith, G. Beck, M. Rashed, V. Adames, M. Linn, E. Wheeldon, L. Gand, H. Birnboeck and G. Hoffmann (2004). Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15(5): 503-512. Hoeller, D., C. M. Hecker and I. Dikic (2006). Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 6(10): 776-788. Hynes, N. E. and H. A. Lane (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5): 341-354. Johnson, C. A., K. Padget, C. A. Austin and B. M. Turner (2001). Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J Biol Chem 276(7): 4539-4542. Kim, H. D., A. Tomida, Y. Ogiso and T. Tsuruo (1999). Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. J Cell Physiol 180(1): 97-104. Kim, M. S., M. Blake, J. H. Baek, G. Kohlhagen, Y. Pommier and F. Carrier (2003). Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63(21): 7291-7300. Krehan, A., R. Schmalzbauer, O. Bocher, K. Ackermann, U. Wirkner, S. Brouwers and W. Pyerin (2001). Ets1 is a common element in directing transcription of the alpha and beta genes of human protein kinase CK2. Eur J Biochem 268(11): 3243-3252. Kristensen, L. S., H. M. Nielsen and L. L. Hansen (2009). Epigenetics and cancer treatment. Eur J Pharmacol 625(1-3): 131-142. Kurz, E. U. and S. P. Lees-Miller (2004). DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 3(8-9): 889-900. Kurz, E. U., S. E. Wilson, K. B. Leader, B. P. Sampey, W. P. Allan, J. C. Yalowich and D. J. Kroll (2001). The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 1(2): 121-131. Li, T., Y. H. Ling, I. D. Goldman and R. Perez-Soler (2007). Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13(11): 3413-3422. Linardou, H., I. J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos, P. Kosmidis, C. A. Papadimitriou and S. Murray (2008). Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9(10): 962-972. Lou, Z., K. Minter-Dykhouse and J. Chen (2005). BRCA1 participates in DNA decatenation. Nat Struct Mol Biol 12(7): 589-593. Lu, Y. S., Y. Kashida, S. K. Kulp, Y. C. Wang, D. Wang, J. H. Hung, M. Tang, Z. Z. Lin, T. J. Chen, A. L. Cheng and C. S. Chen (2007). Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46(4): 1119-1130. Mao, Y., S. D. Desai and L. F. Liu (2000). SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem 275(34): 26066-26073. Marchion, D. C., E. Bicaku, A. I. Daud, D. M. Sullivan and P. N. Munster (2005). In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 4(12): 1993-2000. Marchion, D. C., E. Bicaku, J. G. Turner, A. I. Daud, D. M. Sullivan and P. N. Munster (2005). Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 11(23): 8467-8475. Marks, P., R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller and W. K. Kelly (2001). Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1(3): 194-202. Meggio, F. and L. A. Pinna (2003). One-thousand-and-one substrates of protein kinase CK2? FASEB J 17(3): 349-368. Minucci, S. and P. G. Pelicci (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1): 38-51. Montecucco, A. and G. Biamonti (2007). Cellular response to etoposide treatment. Cancer Lett 252(1): 9-18. Nakajima, T., K. Morita, N. Ohi, T. Arai, N. Nozaki, A. Kikuchi, F. Osaka, F. Yamao and K. Oda (1996). Degradation of topoisomerase IIalpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. J Biol Chem 271(40): 24842-24849. Nakayama, K. I. and K. Nakayama (2006). Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6(5): 369-381. Nayak, M. S., J. M. Yang and W. N. Hait (2007). Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 67(12): 5831-5839. Nitiss, J. L. (2009). DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9(5): 327-337. Nitiss, J. L. (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9(5): 338-350. Norbury, C. J. and B. Zhivotovsky (2004). DNA damage-induced apoptosis. Oncogene 23(16): 2797-2808. Nyati, M. K., M. A. Morgan, F. Y. Feng and T. S. Lawrence (2006). Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 6(11): 876-885. Ogiso, Y., A. Tomida, S. Lei, S. Omura and T. Tsuruo (2000). Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 60(9): 2429-2434. Pao, W. and J. Chmielecki (2010). Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10(11): 760-774. Park, J. H. and T. H. Kim (2005). Release of cytochrome c from isolated mitochondria by etoposide. J Biochem Mol Biol 38(5): 619-623. Piekarz, R. L., A. R. Frye, J. J. Wright, S. M. Steinberg, D. J. Liewehr, D. R. Rosing, V. Sachdev, T. Fojo and S. E. Bates (2006). Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12(12): 3762-3773. Prochazka, V., E. Faber, L. Raida, T. Papajik, J. Vondrakova, Z. Rusinakova, L. Kucerova, M. Myslivecek and K. Indrak (2011). Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 155(1): 63-69. Redwood, C., S. L. Davies, N. J. Wells, A. M. Fry and I. D. Hickson (1998). Casein kinase II stabilizes the activity of human topoisomerase IIalpha in a phosphorylation-independent manner. J Biol Chem 273(6): 3635-3642. Rikiishi, H. (2011). Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011: 830260. Roos, W. P., L. F. Batista, S. C. Naumann, W. Wick, M. Weller, C. F. Menck and B. Kaina (2007). Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26(2): 186-197. Sangha, R., P. N. Lara, Jr., P. C. Mack and D. R. Gandara (2009). Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol 21(2): 116-123. Shapiro, P. S., A. M. Whalen, N. S. Tolwinski, J. Wilsbacher, S. J. Froelich-Ammon, M. Garcia, N. Osheroff and N. G. Ahn (1999). Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol 19(5): 3551-3560. Sharma, S. V., D. W. Bell, J. Settleman and D. A. Haber (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3): 169-181. Shiloh, Y. (2003). ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3(3): 155-168. Staker, B. L., K. Hjerrild, M. D. Feese, C. A. Behnke, A. B. Burgin, Jr. and L. Stewart (2002). The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 99(24): 15387-15392. Sunter, N. J., I. G. Cowell, E. Willmore, G. P. Watters and C. A. Austin (2010). Role of Topoisomerase IIbeta in DNA Damage Response following IR and Etoposide. J Nucleic Acids 2010. Trembley, J. H., G. Wang, G. Unger, J. Slaton and K. Ahmed (2009). Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 66(11-12): 1858-1867. Tsai, S. C., N. Valkov, W. M. Yang, J. Gump, D. Sullivan and E. Seto (2000). Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 26(3): 349-353. Turner, J. G., R. Engel, J. A. Derderian, R. Jove and D. M. Sullivan (2004). Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signals. J Cell Sci 117(Pt 14): 3061-3071. Uhle, S., O. Medalia, R. Waldron, R. Dumdey, P. Henklein, D. Bech-Otschir, X. Huang, M. Berse, J. Sperling, R. Schade and W. Dubiel (2003). Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J 22(6): 1302-1312. Valkov, N. I. and D. M. Sullivan (2003). Tumor p53 status and response to topoisomerase II inhibitors. Drug Resist Updat 6(1): 27-39. Wei, N., G. Serino and X. W. Deng (2008). The COP9 signalosome: more than a protease. Trends Biochem Sci 33(12): 592-600. Welcker, M. and B. E. Clurman (2008). FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8(2): 83-93. Yonesaka, K., K. Tamura, T. Kurata, T. Satoh, M. Ikeda, M. Fukuoka and K. Nakagawa (2006). Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 118(4): 812-820. Yoshida, K., T. Yamaguchi, H. Shinagawa, N. Taira, K. I. Nakayama and Y. Miki (2006). Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage. Mol Cell Biol 26(9): 3414-3431. Yoshino, M., N. Okazaki, T. Yoshida, Y. Kanda, M. Miki, H. Oda, Y. Sasagawa, S. Hayashi and N. Hashimoto (1989). A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group. Jpn J Clin Oncol 19(2): 120-122. Yun, J., A. Tomida, T. Andoh and T. Tsuruo (2004). Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5. J Biol Chem 279(30): 31296-31303. Zhou, B. B. and J. Bartek (2004). Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 4(3): 216-225. Zhou, M., L. Gu, F. Li, Y. Zhu, W. G. Woods and H. W. Findley (2002). DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 303(1): 124-131. Zinkel, S., A. Gross and E. Yang (2006). BCL2 family in DNA damage and cell cycle control. Cell Death Differ 13(8): 1351-1359. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16550 | - |
dc.description.abstract | 在台灣的十大癌症死亡率排行榜中,肺癌與肝癌分別為第一、二名。即使經過幾十年的研究,至今我們依然在找尋更好的治療策略。
Topo II在哺乳類細胞的分裂過程中是一個必須的酵素,並用來維持DNA的topology,在腫瘤細胞中也常見topo II過度表現的現象。作用在topo II的抗癌藥物可以導致DNA的斷裂以及引起致命的細胞凋亡。除了傳統的化學治療,作用在HDAC上的HDAC inhibitors以及作用在其他標靶的藥物(例如EGFR)都廣為被用來研究癌症的治療。在本篇論文當中,我們就以HDAC inhibitor,topo II-targeting drug以及合併治療為研究對象,探討在腫瘤細胞內所調控的訊息傳遞。 HDAC inhibitors可以干擾HDAC的活性,對於藥物開發針對廣泛的抗癌治療是很有希望的。第一部分,我們報導的HDAC inhibitor,AR42(也稱之為OSU-HDAC42),之前已經發現 AR42在in vivo可以有效的抑制肝癌細胞,且這現象是經由藥物作用在histone acetylation-dependent以及-independent的兩個路徑。在本篇我們則是報導AR42在人類肝癌細胞(hepatocellular carcinoma)中引起topo IIα降解的新作用機制。研究結果顯示此一HDAC inhibitor可以藉由增加acetylated histone H3至CK2α的promoter達到活化CK2α的轉錄,接著CK2α可以促進topo IIα磷酸化並藉著磷酸化的topo IIα和COP9其中的subunit Csn5相結合。我們更進一步發現一個會和Csn5有交互作用的F-box蛋白-Fbw7,為負責此topo IIα降解的E3-ligase。 本論文的第二部分則是探討一個新的etoposide衍生物,QS-ZYX-1-61,在A549細胞中的藥效強度(IC50)比etoposide高100倍且具備良好的活性造成DNA雙股斷裂,並啟動DNA damage response導致最後的細胞凋亡。藥物處理之下可以活化ATM、Chk2並造成細胞內p53的累積。為了研究QS-ZYX-1-61對於topoisomerase的作用,利用DNA relaxation assay以及band-depletion assay發現藥物可以抑制topoisomerase II的酵素活性並在細胞內形成可逆的cleavable complexes。我們若更進一步的減少細胞內p53, topo IIα, IIβ的表現,則可以減少QS-ZYX-1-61原本所活化的caspase 3、PARP、以及細胞生長的抑制,顯示藥物在細胞內造成細胞凋亡需要經由這些蛋白的作用。我們的研究更證實QS-ZYX-1-61為一個新的DNA damage agent並值得應用於非小型肺癌細胞的治療。 Erlotinib(Tarceva)為口服的小分子標靶抑制劑,以可逆的方式結合到EGFR細胞內的tyrosine kinase domain,用來為治療非小型細胞肺癌,如此一來就會阻斷EGFR的autophosphorylation以及下游的訊息傳遞。本論文的最後一個部分,則是利用測量細胞的生長抑制、細胞週期的分佈、以及細胞凋亡訊號的表現,專注於erlotinib-resistant的細胞A549來做抗癌效果的觀察學習。當細胞暴露在erlotinib和新的口服HDAC inhibitor MTP0E028時,可以在erlotinib-resistant的人類非小型細胞肺癌(A549, H1299以及NCI-H1975)內觀察到加成性的毒殺作用。在in vitro我們可以看到抑制細胞生長、acetylated histone H3以及acetylated tubulin的增加、PARP cleavage,γH2AX的增加,以及caspase-3的活化。同時也在癌症動物模式中確認到相同的細胞訊號反應,也證實此合併投予藥物在動物體內為可容忍劑量。根據這些發現,可以在非小型細胞肺癌內評估合併TKI (tyrosine kinase inhibitor)以及HDAC inhibitor的策略,並分析導致此加成性藥理作用的分子機制。 | zh_TW |
dc.description.abstract | According to recent reports on the top ten leading causes of cancer death, lung cancer and liver cancer still take first and second place in Taiwan. After decades of research, we are still trying to find better therapeutic strategies to cure cancers.
Topoisomerase II is an essential enzyme to maintain DNA topology in mammalian cells and is often overexpressed in tumor cells. Targeting topoisomerase II in cancer treatment leads to DNA breaks and lethal apoptotic cell death. In addition to conventional chemotherapy, HDAC inhibitors, and other target theapies also have been studied and evaluated for cancer treatment strategy. In this thesis, we investigated HDAC inhibitor, topo II-targeting drug, and combination cancer therapy in regulating tumor cells signalings. HDAC inhibitors that interfere HDAC activity have been shown promising evidences in drug development for broad spectrum anti-cancer therapy. In the first chapter, we reported a novel phenylbutyrate-derived histone deacetylase (HDAC) inhibitor AR42 (formerly OSU-HDAC42) exhibiting high in vivo potency in suppressing HCC tumor growth, which was previously shown attributable to its ability to target both histone acetylation-dependent and -independent pathways. Here we reported a novel pathway by which HDAC inhibitor AR42 mediated topo IIα proteolysis in HCC cells. Our data indicate that this HDAC inhibitor (AR42) transcriptionally activated casein kinase (CK)2α expression through increased association of acetylated histone H3 with the CK2α gene promoter. In turn, CK2 facilitated the binding of topo IIα to COP9 signalosome subunit (Csn)5 by way of topo IIα phosphorylation. Furthermore, we identified Fbw7, a Csn5-interacting F-box protein, as the E3 ligase that targeted topoIIα for degradation. In the second chapter, we evaluated a novel etoposide analogue, QS-ZYX-1-61, which exhibits 100 folds more potency than etoposide in A549 cells. QS-ZYX-1-61 displays an outstanding activity by which induces DNA double-strand breaks and DNA damage response signaling. We showed activation of ATM (ataxia telangiectasia mutated), Chk2 (checkpoint kinase 2), and accumulation of p53 after QS-ZYX-1-61 treatment in A549 cells. To determine the effect of QS-ZYX-1-61 on topoisomerase, we used DNA relaxation assay and band-depletion assay to show that QS-ZYX-1-61 inhibits enzyme activity of topo IIα and induces reversible cleavable complexes in cells. Moreover, blocking of p53, topo IIα, and topo IIβ greatly protected against caspase-3 activation, poly-ADP-ribose polymerase cleavage and cell growth inhibition, indicating that QS-ZYX-1-61 acts through these proteins. Our data suggest that QS-ZYX-1-61 is a novel DNA damage agent that could be applied as targeted therapeutic drug for NSCLC. Tyrosine kinase inhibitor (TKI) elotinib (Tarceva) is an oral small molecule inhibitor which reversibly binds to the intracellular tyrosine kinase domain of epidermal growth factor receptor and is used to treat non-small cell lung cancer. This agent blocks autophosphorylation of EGFR with subsequent inhibition of downstream signaling pathways. In the last chapter, we focused on erlotinib-resistant cells (A549 cells) and studied the antitumor effect by measuring growth inhibition, cell cycle distribution, and expression of apoptotic signals by immunoblots. When cells were exposed to erlotinib and MPTOE028, a novel pan-HDAC inhibitor, cytotoxic synergism was observed in erlotinib-resistant human NSCLC cell lines (A549, H1299 and NCI-H1975). We showed the synergistic effect of MPTOE028 in combination with erlotinib, exhibiting EGFR downregulation, growth inhibition, increased level of acetylated histone H3 and acetylated tubulin, PARP cleavage, γH2AX increased, and caspase-3 activation in vitro. Xenografting experiments confirmed the in vitro activity and tolerability of the combination. Based on these findings, the combination of tyrosine kinase inhibitor and HDAC inhibitor for relapsing NSCLC has to be evaluated and analyzed regarding the molecular basis for this synergistic effect. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T18:20:18Z (GMT). No. of bitstreams: 1 ntu-101-F94443012-1.pdf: 26117112 bytes, checksum: 01bcc186ab8175562e56acc0a91568bf (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 口試委員會審定書
縮寫表……………………………………………………………………………………i 中文摘要………………………………………………………………………………...1 英文摘要………………………………………………………………………………...3 第一章 第一節 研究動機與目的…………………………………………………………..7 第二節 文獻回顧…………………………………………………………………..9 第二章 實驗材料與方法 第一節 實驗材料……………………………………………………………........51 第二節 實驗方法……………………………………………………………........53 第三章 HDAC抑制劑在肝癌細胞中促使第二型拓樸異構酶分解的機制探討 中文摘要…………………………………………………………….....................58 英文摘要…………………………………………………………….....................59 第一節 結果……………………………………………………………................61 第二節 討論……………………………………………………………................67 第四章 QS-ZYX-1-61在人類非小型細胞肺癌中經由topoisomerase II造成細胞凋亡 中文摘要…………………………………………………………….....................82 英文摘要…………………………………………………………….....................83 第一節 結果……………………………………………………………................84 第二節 討論……………………………………………………………................87 第五章 合併erlotinib和HDAC inhibitor MPT0E028在人類非小型細胞肺癌上的 加成作用 中文摘要……………………………………………………………...................102 英文摘要……………………………………………………………...................103 第一節 結果……………………………………………………………..............104 第二節 討論……………………………………………………………..............106 第六章 總結與展望…………………………………………………………………..117 著作……………………………………………………………………………….......119 參考文獻………………………………………………………………………….......120 | |
dc.language.iso | zh-TW | |
dc.title | "AR42, QS-ZYX-1-61,及erolotinib和MPT0E028併用之抗腫瘤藥效與機制探討" | zh_TW |
dc.title | Effects and action mechanisms of AR42, QS-ZYX-1-61, and combination of erlotinib-MPT0E028 in cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-1 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 陳慶士(Ching-Shih Chen),潘秀玲(Shiow-Lin Pan) | |
dc.contributor.oralexamcommittee | 黃德富(Tur-Fu Huang),顧記華(Jih-Hwa Guh),楊春茂(Chuen-Mao Yang),顏茂雄(Mao-Hsiung Yen) | |
dc.subject.keyword | 肝癌,肺癌,細胞凋亡,DNA損害,拓撲異構酶, | zh_TW |
dc.subject.keyword | Hepatocellular carcinoma,lung cancer,apoptosis,DNA damage,topoisomerase, | en |
dc.relation.page | 123 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2012-01-10 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 25.5 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。